Effect of interleukin 10 on the release of the CXC chemokines growth related oncogene GRO-alpha and epithelial cell-derived neutrophil activating peptide (ENA)-78 during human endotoxemia

Immunol Lett. 2001 Aug 1;78(1):41-4. doi: 10.1016/s0165-2478(01)00224-3.

Abstract

Pretreatment with interleukin (IL)-10 inhibited the release of growth-related oncogene GRO-alpha but not of epithelial-cell derived neutrophil activating protein (ENA)-78, after injection of lipopolysaccharide (LPS) into healthy humans. In vitro, IL-10 dose-dependently attenuated LPS-induced release of both GRO-alpha and ENA-78 in whole blood and in cultures of isolated polymorphonuclear and mononuclear cells.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Chemokine CXCL1
  • Chemokine CXCL5
  • Chemokines, CXC / analysis*
  • Chemotactic Factors / analysis*
  • Double-Blind Method
  • Endotoxemia / chemically induced
  • Endotoxemia / drug therapy*
  • Endotoxemia / immunology
  • Growth Substances / analysis*
  • Humans
  • Injections, Intravenous
  • Intercellular Signaling Peptides and Proteins*
  • Interleukin-10 / therapeutic use*
  • Interleukin-8 / analogs & derivatives
  • Interleukin-8 / analysis*
  • Leukocytes, Mononuclear / immunology
  • Lipopolysaccharides / antagonists & inhibitors
  • Male
  • Neutrophils / immunology

Substances

  • CXCL1 protein, human
  • CXCL5 protein, human
  • Chemokine CXCL1
  • Chemokine CXCL5
  • Chemokines, CXC
  • Chemotactic Factors
  • Growth Substances
  • Intercellular Signaling Peptides and Proteins
  • Interleukin-8
  • Lipopolysaccharides
  • Interleukin-10